HTS Facility

Recent advances in molecular biology and genomics research are leading to the discovery of new drug targets. At the same time, improved assay methods have become available for virtually all target classes. This offers enormous opportunities for biotech and pharmaceutical companies to fully exploit the potential of high-throughput-screening (HTS) to develop new drug candidates.

BRI's HTS Facility offers industrial clients, as well as academic and NRC researchers, the opportunity to efficiently and confidentially screen extensive compound libraries at a reasonable cost. The HTS Facility provides access to small molecule collections and assistance in conducting and interpreting high-throughput screens.

Service highlights

• Primary and secondary screening
• Throughput up to 25,000 compounds per day
• Assay optimization and validation
• 96-well or 384-well assay plate format
• In-house public libraries (> 100,000 compound) with broad base applicability
• Customized and flexible approach to meet your needs
• Compatibility with most assay types and readout modes, as well as in vitro and cell-based assays, for maximum flexibility.
• Guidance from BRI scientists regarding:
  • identification of the most suitable assay and detection method
  • assay optimization and hit confirmation
  • additional SAR or kinetic analysis